This represents a novel mechanism of GBA1-derived PD risk and an attractive candidate for precision-based therapeutics in a remarkably underserved population 7, reinforcing the idea that distinct genetic architectures contribute to disease susceptibility and in turn could inform optimized treatment options in the future. This evidence concerns the gene GBA1 and Parkinson disease.